المؤلفون: Karl Anton Kreuzer, Maria R. Baer, Lucy A. Godley, Nozar Azarnia, Robert H. Collins, Elias Jabbour, Suman Kambhampati, Lewis R. Silverman, Hagop M. Kantarjian, Ehab Atallah, Guillermo Garcia-Manero, Gail J. Roboz, Francois Wilhelm, Aref Al-Kali, Mikkael A. Sekeres, Peter L. Greenberg, Uwe Platzbecker, Bart L. Scott, David P. Steensma, Pierre Fenaux, Gianluca Gaidano

المصدر: The Lancet Oncology. 17:496-508

مصطلحات موضوعية: Male, Risk, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Population, Glycine, Kaplan-Meier Estimate, Neutropenia, Decitabine, Disease-Free Survival, Drug Administration Schedule, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, medicine, Humans, Sulfones, education, Aged, education.field_of_study, business.industry, Standard treatment, Hazard ratio, Rigosertib, DNA Methylation, Middle Aged, medicine.disease, Europe, Treatment Outcome, 030104 developmental biology, Oncology, International Prognostic Scoring System, Myelodysplastic Syndromes, 030220 oncology & carcinogenesis, Azacitidine, Female, business, Febrile neutropenia

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca6b04ff53199561af227ff83eb0217
https://doi.org/10.1016/s1470-2045(16)00009-7